AAAAAA

   
Results: 1-9 |
Results: 9

Authors: Hirth, J Watkins, PB Strawderman, M Schott, A Bruno, R Baker, LH
Citation: J. Hirth et al., The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance, CLIN CANC R, 6(4), 2000, pp. 1255-1258

Authors: Baker, LH Bahnson, RR Hanks, GE Huben, RP Kantoff, P Kozlowski, JM Kuettel, M Lange, PH Logothetis, C Pow-Sang, JM Roach, M Sandler, H Scardino, PT Taylor, RJ Urban, DA Walsh, PC Wilson, TG
Citation: Lh. Baker et al., NCCN Practice Guidelines for prostate cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 111-119

Authors: Williamson, SK Lew, D Miller, GJ Balcerzak, SP Baker, LH Crawford, ED
Citation: Sk. Williamson et al., Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma - A Southwest Oncology Group study, CANCER, 88(5), 2000, pp. 1159-1165

Authors: Seifman, BD Wei, JT Sonnad, SS Smith, DC Montie, JE Baker, LH
Citation: Bd. Seifman et al., Comparing current care to the NCCN prostate cancer practice guidelines, ONCOLOGY-NY, 13(11A), 1999, pp. 133-142

Authors: Baker, LH Biermann, S
Citation: Lh. Baker et S. Biermann, NCCN practice guidelines: Bone cancers, ONCOLOGY-NY, 13(11A), 1999, pp. 365-389

Authors: Sugawara, Y Zasadny, KR Kison, PV Baker, LH Wahl, RL
Citation: Y. Sugawara et al., Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results, J NUCL MED, 40(9), 1999, pp. 1456-1462

Authors: Biermann, JS Golladay, GJ Greenfield, MLVH Baker, LH
Citation: Js. Biermann et al., Evaluation of cancer information on the Internet, CANCER, 86(3), 1999, pp. 381-390

Authors: Biermann, JS Baker, LH
Citation: Js. Biermann et Lh. Baker, Soft tissue sarcoma - Opening the door to advances in diagnosis and treatment, CANCER, 85(12), 1999, pp. 2497-2498

Authors: Weiss, GR Liu, PY Alberts, DS Peng, YM Fisher, E Xu, MJ Scudder, SA Baker, LH Moore, DF Lippman, SM
Citation: Gr. Weiss et al., 13-cis-retinoic acid or all-trans-retinoic acid plus inteferon-alpha in recurrent cervical cancer: A Southwest Oncology Group phase II randomized trial, GYNECOL ONC, 71(3), 1998, pp. 386-390
Risultati: 1-9 |